Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02470936
Other study ID # 14-13555
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2015
Est. completion date March 2018

Study information

Verified date February 2019
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized controlled trial of a technology-based lifestyle intervention vs. usual care among men with low-risk prostate cancer to determine the feasibility and acceptability of the intervention and the effect of the intervention on behavior change related to exercise, diet, and not smoking.


Description:

This is a PI-initiated, randomized, unblinded, clinical trial of a technology-based 3 month lifestyle intervention vs. usual care among men with low risk prostate cancer. We will recruit and consent 76 men with prostate cancer at UCSF. The subjects will be asked to complete questionnaires, 7 days accelerometer measurement, body measurements (weight, waist, hip, pulse, blood pressure) and collection of blood specimen at baseline and 3 months. Subjects will be randomized into two arms (Intervention Group and Control Group). The Intervention Group (N=38) will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive text messages, and be provided with individualized lifestyle recommendations. The Control Group (N=38) will have standard of care and be asked to continue with their usual lifestyle habits. They will receive access to the lifestyle website and be provided with individualized lifestyle recommendations at 3 months.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date March 2018
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. clinical stage =T3a nonmetastatic prostate cancer within 5 years

2. completion of treatment =3 months prior to enrollment, if not on active surveillance

3. ability to walk unassisted

4. be able to speak and read English

5. ability to navigate websites and email, and have internet access

6. able to travel to UCSF for pre- and post-study blood collection

Exclusion Criteria:

1. any contraindications to moderate or vigorous aerobic exercise

2. psychiatric condition preventing the patient from giving informed consent or adhering to the study protocol

3. reporting adherence to more than 4 of the 8 targeted lifestyle behaviors via questionnaires at screening

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Lifestyle intervention
Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.

Locations

Country Name City State
United States University of California, San Francisco (UCSF) San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
University of California, San Francisco American Cancer Society, Inc., Prostate Cancer Foundation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kenfield SA, Van Blarigan EL, Ameli N, Lavaki E, Cedars B, Paciorek AT, Monroy C, Tantum LK, Newton RU, Signorell C, Suh JH, Zhang L, Cooperberg MR, Carroll PR, Chan JM. Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer. Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31048-0. doi: 10.1016/j.eururo.2018.12.040. [Epub ahead of print] — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Fitbit use We will measure the number of days the Fitbit was used during the study period in the intervention arm only to assess study feasibility 3 months
Primary text message use We will measure the number of text messages responded to that required a reply in the intervention arm only during the study period to assess study feasibility 3 months
Primary website use - number of days the website was visited We will measure the total number of days the website was visited in the intervention arm only during the study period to assess study feasibility 3 months
Primary website use - number of website visits We will measure the total number of website visits in the intervention arm only during the study period to assess study feasibility 3 months
Primary intervention acceptability We will assess intervention acceptability via questionnaire at 3 months in the intervention group. 3 months
Primary self-reported change in health behaviors We will assess change in health behaviors via questionnaire at baseline and 3 months. 3 months
Secondary change in physical activity measured by activity monitor This is assessed via 7-day accelerometer measurements at baseline and 3 months. 3 months
Secondary change in task self-efficacy We will assess confidence in performing behaviors via questionnaire at baseline and 3 months. 3 months
Secondary change in plasma antioxidant Vitamin E We will assess Vitamin E levels at baseline and 3 months. 3 months
Secondary change in plasma antioxidant lycopene We will assess lycopene levels at baseline and 3 months. 3 months
Secondary change in fasting glucose We will assess fasting glucose at baseline and 3 months. 3 months
Secondary change in cholesterol We will assess cholesterol at baseline and 3 months. 3 months
Secondary change in hemoglobin A1c We will assess hemoglobin A1c at baseline and 3 months. 3 months
Secondary change in C-reactive protein We will assess C-reactive protein at baseline and 3 months. 3 months
Secondary change in waist circumference We will assess waist circumference at baseline and 3 months. 3 months
Secondary change in weight We will assess weight at baseline and 3 months. 3 months
Secondary change in body mass index We will assess body mass index at baseline and 3 months. 3 months
Secondary depression Center for Epidemiologic Studies Depression Scale completed at baseline and 3 months. 3 months
Secondary anxiety Memorial Anxiety Scale for Prostate Cancer and State Anxiety completed at baseline and 3 months. Trait anxiety completed at baseline. 3 months
Secondary health-related quality of life Expanded Prostate Cancer Index Composite-26 and Short Form Health Survey-36 completed at baseline and 3 months. 3 months
Secondary maintenance or adoption of self-reported behaviors after 1 year We will assess change in health behaviors via questionnaire at baseline, 3 months, and 1 year. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A